Related Experiment Video
Updated: Oct 14, 2025

11:21
Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
Published on: January 20, 2022
3.6K
Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies.
Elene Davitashvili1, George Burjanadze2, Marine Koshoridze2
1Department of Biology, Chair of Biochemistry, Faculty of Exact and Natural Sciences, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia. elene.davitashvili@tsu.ge.
Molecular Biology Reports
|November 5, 2021
Summary
Galectins, which are galactose-specific lectins, show varied effects on cell viability and apoptosis depending on their source in prostate tissues. This suggests galectins from cancerous tissues may suppress immune function.
Area of Science:
- Molecular biology
- Immunology
- Biochemistry
Background:
- Galectins (galactose-specific lectins) are crucial in cell activities like apoptosis and transformation.
- Galectins are implicated in prostate cancer development.
- The differential expression and function of galectins in various prostate pathologies remain unclear.
Purpose of the Study:
- To investigate if different grades of prostate pathologies express distinct galectins.
- To determine if these galectins exert varied effects on cell viability.
Main Methods:
- Purification of cytosolic galactose-specific lectin fractions from prostate tissues using affinity chromatography.
- Analysis of lectin fractions via SDS-PAGE.
- Assessment of lectin effects on peripheral lymphocyte viability (MTT assay) and apoptosis (flow cytometry).
Main Results:
- Purified lectin fractions from normal and pathological prostate tissues exhibited different protein compositions.
- These lectins demonstrated distinct impacts on cell viability and apoptosis.
- Effects were found to be source-dependent.
Conclusions:
- Cytosolic galactose-specific lectins' effects are contingent on the glandular tissue's disease state.
- Released galectins from high-grade intraepithelial neoplasia and adenocarcinoma may potentially suppress host immune status.

